MAPT and Alzheimer disease: To further validate the involvement of GPNMB+ microglia in the Aβ-tau interaction in early-stage AD, we used another large-scale snRNA-seq data set for microglia subtypes in AD,[21] including transcriptome data for 194,000 single-nuclear microglia and multiple AD pathological phenotypes in 443 human subjects.